Komori
K

KYORIN Pharmaceutical Co.,Ltd.

4569PharmaceuticalsSmall cap
1,119JPY+1.3%
★ Watch (sign-up required)
Price history
¥1,119Latest-33.7%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

The Group’s core business is the manufacture and sale of pharmaceuticals, and it operates as a single pharmaceutical business segment. The Group comprises 4 companies in total, including the Company (the filing company) and 2 affiliated companies, and is primarily engaged in the manufacture and sale of pharmaceuticals. The business structure and status of affiliated companies are as follows.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Documents
See all timely disclosuresSee all statutory filings
News
See all news
Key numbersShowing 8 of 20
PER
81.41How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.
PBR
0.48How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
0.6%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥67bnShare price × number of shares. The value of the entire company.
Equity ratio
74.4%The proportion of assets funded by money that does not have to be repaid.
Operating margin
3.3%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
2.1%The average annual growth in sales over the past three years.
What to watch next
Clinical development progress, including the start of the confirmatory trial for KRP-DT123 and progress in preparations for trials of KRP-DC125
Impact MediumLikelihood Medium
Wider adoption of GeneSoC mini 2, launched in October 2024, and increased contribution to sales
Impact MediumLikelihood Medium
Changes in the earnings structure following the planned transfer of the generic drug business on 1 April 2027
Around April 2027Impact HighLikelihood Medium
Reassessment of the earnings environment following drug price revisions as part of domestic healthcare cost-containment measures
Annually, depending on the systemImpact HighLikelihood High
What to watch next
Loading
Who owns itTop holders total 47.4%
Listed holders 47.4%Everyone else 52.6%
The Master Trust Bank of Japan, Ltd. (Trust Account)10.41%
株式会社マイカム8.90%
株式会社ルキウス4.84%
Custody Bank of Japan, Ltd. (Trust Account).3.79%
キョーリン製薬グループ持株会3.59%
FREEDOM VALLEY DRIVE OAKS PENNSYLVANIA 194563.43%
株式会社バンリーナ3.35%
株式会社アーチァンズ3.35%
2 other listed holders5.77%
Who owns it
HolderOwnership (%)
The Master Trust Bank of Japan, Ltd. (Trust Account)10.41
株式会社マイカム8.90
株式会社ルキウス4.84
Custody Bank of Japan, Ltd. (Trust Account).3.79
キョーリン製薬グループ持株会3.59
FREEDOM VALLEY DRIVE OAKS PENNSYLVANIA 194563.43
株式会社バンリーナ3.35
株式会社アーチァンズ3.35
2 other listed holders5.77
This company's documents
Filings
Timely disclosures
Threads